Ø payload is not released prior to contact/

Ø  Target
selection; Only targets cancer cells and appears at negligibles elsewhere.

Ø  High
quality; provides best carrier molecule with highest standard properties.

Best services for writing your paper according to Trustpilot

Premium Partner
From $18.00 per page
4,8 / 5
Writers Experience
Recommended Service
From $13.90 per page
4,6 / 5
Writers Experience
From $20.00 per page
4,5 / 5
Writers Experience
* All Partners were chosen among 50+ writing services by our Customer Satisfaction Team

Ø  Binding
and ability to attach and enter cancer cell.

Ø  Potency
of toxin and a platform that can transport it to and allow it to work on the
cancer cell with a low target expression.

Ø  Bond
strength of toxin to antibody; linker must be strong so payload is not released
prior to contact/ insertion with tumour.

Ø  Conjugation
site and potency of toxin.



•       Developed
by Wyeth Pharmaceuticals, a branch of Pfizer.

•       This
ADC was approved by the U.S. FDA on August 17, 2017. For use in the treatment
of adults who have experienced a relapse or refractory B-cell precursor
lymphoblastic leukaemia.

•       326
patients were involved in the study involving Besponsa. Of these 326 patients a
random amount received Besponsa (164) or a choice of chemotherapy (162). Of 218
initially randomized patients, 35.8% of these who were treated with Besponsa
went into full remission for an average of 8 months and 89.7% had very little
continual disease. 17.4% of the chemotherapy patients experienced a complete
remission averaging around 4.9 months and 31.6% had minimal continual disease.

•       Side
effects common in greater than 20% of patients. (fatigue, anaemia, nausea)
mostly the same as those associated with chemotherapy. 


•       Commonly
known as Mylotarg and also manufactured by Wyeth Pharmaceuticals.

•       Mainly
used in the treatment of CD33 positive acute myeloid leukaemia (AML) in patients
who are in their first relapse, are over the age of 60 and when no other
chemotherapy is recommended. The drug has also been approved to treat children
of 2 years or older who have relapsed and not responded to initial treatment. It
works by also forming bone marrow that results in an increase of white blood
cells in the blood.

•       It
was originally approved in May 2000 then removed from the market in 2010
because of repeatedly failed clinical trials, mainly due to a high amount of
premature deaths was a large factor. Mylotarg was reintroduced in 2017
featuring a lower dosage and a new schedule along with chemotherapy. AML is
gaining momentum and a progressive form of treatment for cancer.

•       Trialled
in 271 random patients, with one group received mylotarg with daunorubicin and
cytarabine and the second group received the same but without the mylotarg. The
goal of the trial was to measure how long patients went without specific
complications, mainly negative response to treatment, relapse of disease, or
death. The study showed that those receiving mylotarg along with chemotherapy
went a longer period of time without complications than those receiving only
chemotherapy. Survival rate, 17.3 months (mylotarg) vs. 9.5 months (Chemotherapy